Latest Kidney Cancer News
Type of Long-term Response to Targeted mRCC Therapy Affects Outcomes
Patients who have a complete response to 2 or more years of anti-VEGF treatment have the best progression-free and overall survival.
BMI, Belly Fat Suggest Obesity-Related Cancer Risk
BMI and location of excess body fat on the body are good indicators of obesity-related cancer risk.
Renal, Bladder Cancer Linked to Physical Inactivity
Renal and bladder cancer patients were, respectively, 77% and 73% more likely to report lifetime physical inactivity than controls without cancer.
AUA Releases Updated Renal Mass Guidelines
The document spells out in greater detail the criteria for radical and partial nephrectomy and for placing patients on active surveillance.
Early CRP Response to mRCC Drugs Predicts Survival
Changes in C-reactive protein levels 4 weeks after starting sunitinib or sorafenib treatment are associated with overall and progression-free survival.
AS Safe for Cystic Renal Masses in Selected Patients
In a single-center study, 24% of patients crossed over to treatment and 95% of patients were alive after 5 years of follow-up.
RCC Patients May Benefit from Nivolumab After Disease Progression
Nivolumab treatment beyond disease progression results in reductions in tumor burden, study finds.
Recurrence of Low-Risk RCC Uncommon After Surgery
In a study, the 5-year risk of recurrence was 4.8%, 18.1%, and 46.3% for patients with low-, intermediate-, and high-risk disease.
Kidney Cancer Survival Better Among Metformin Users
Patients who used the drug had a 38% lower risk of dying from kidney cancer than non-users, meta-analysis shows.
Targeted Therapies for Advanced RCC Improve Real-World Survival
Overall survival among patients receiving first-line targeted therapy for advanced renal cell carcinoma increased significantly from 2006 to 2012.
Kidney Cancer Linked to Obesity
Study also finds associations between adiposity and 10 other cancers, particularly digestive and hormone-related malignancies.
Broad-spectrum Antibiotics May Reduce Survival in mRCC
The researchers found that patients treated with ABT had decreased progression-free survival compared with those not receiving ATB.
Biologics Combo Shows Promise As First-Line mRCC Therapy
In a phase 2 trial, atezolizumab plus bevacizumab improved PFS versus sunitinib in patients with renal cell carcinoma expressing PD-L1.
Sunitinib Dose Escalation May Benefit mRCC Patients
Added progression-free survival and prolonged overall survival possible, according to investigators.
Kidney Cancer Brain Metastases Not On the Rise
Researchers develop a model to predict which patients are more likely to harbor brain metastases at cancer diagnosis.
Renal and Urology News Articles
- Active Surveillance for Intermediate-risk Prostate Cancer Challenged
- Ferritin Spike Soon After Hemodialysis Initiation Ups Mortality Risk
- Type of Long-term Response to Targeted mRCC Therapy Affects Outcomes
- Add-on Sevelamer Therapy May Improve Hemodialysis Patient Survival
- Hypothyroidism Tied to Worse Quality of Life for HD Patients
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Anemia
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetes
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Hemodialysis
- Hyperphosphatemia
- Hypertension
- Hyperuricemia
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)
- Transplantation